TrialThe Journal of clinical endocrinology and metabolism2023

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.

George J Kahaly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.